Trends in HIV-1 Reverse Transcriptase Resistance-Associated Mutations and Antiretroviral Prescription Data from 2003–2010
- 1 August 2012
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (6) , 993-999
Abstract
Background: The selection of antiretroviral (ARV) drugs for treatment of HIV-1 infection is based on several factors including potency, toxicity, resistance and ease of administration. Emtricitabine (FTC) or lamivudine (3TC), components of recommended initial ARV regimens, are structurally related and share the same resistance mutation (M184V/I). However they differ with respect to potency and incidence of M184V/I. Methods: Resistance-associated mutation (RAM) prevalence data were obtained from genotype test results performed in a large reference laboratory from 2003–2010; subsets of data were defined by mutation pattern to resemble those following failure of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination therapy. Mutational trend data were compared to contemporaneous ARV prescription information. Results: In the unfiltered data set ( n=107,231), the prevalence in 2010 decreased compared to 2003 for all nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) RAMs, such as M184V/I (44.0% to 17.9%), T215Y (22.7% to 4.1%), and K65R (4.3% to 2.1%). Among samples resembling those typical of first-line NNRTI-based failures, prevalence of K103N increased slightly, but prevalence of M184V/I decreased (49.8% to 36.8%), as did other NRTI RAMs. These decreases were coincident with a shift in ARV prescriptions away from zidovudine and 3TC towards tenofovir and FTC, and an increase in use of fixed-dose combinations. Conclusions: RAM prevalence decreased substantially since 2003 among samples submitted for resistance testing in the US. The causes of this decrease are multifactorial, but our results suggest a possible role of increased use of potent ARVs that are available as fixed-dose combinations or as single-tablet regimens.Keywords
This publication has 32 references indexed in Scilit:
- Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabineAIDS, 2010
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 TherapyNew England Journal of Medicine, 2009
- The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir☆Infection, Genetics and Evolution, 2009
- Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infectionStatistics in Medicine, 2007
- Resistance development over 144 weeks in treatment‐naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903*HIV Medicine, 2006
- Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug‐Resistant HIV‐1 InfectionThe Journal of Infectious Diseases, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2003
- Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical IsolatesThe Journal of Infectious Diseases, 2003
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995